Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.
Journal: The oncologist
Published: February 09, 2026
Cachexia in Pancreatic Cancer: New Insights to Impact Quality of Life and Survival.
Journal: Nutrients
Published: August 04, 2025
Racial Disparities in Non-Stigmatized Supportive Care Medication Use in Pancreatic Cancer.
Journal: Journal of pain and symptom management
Published: July 25, 2025
Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
Journal: JCO precision oncology
Published: May 22, 2025
Racial Disparities in Analgesic and Psychiatric Medication Use During End-Of-Life Care in Advanced-Stage Colorectal Cancer: A Retrospective Cohort Study.
Journal: Cancer research communications
Published: March 21, 2025
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
Journal: JCO precision oncology
Published: December 03, 2024
ECM Stiffness-Induced Redox Signaling Enhances Stearoyl Gemcitabine Efficacy in Pancreatic Cancer.
Journal: Cancers
Published: December 02, 2024
A novel gemcitabine analog as a potential anticancer agent: synthesis and in-vitro evaluation against pancreatic cancer.
Journal: American journal of cancer research
Published: November 01, 2024
Executing plans to enhance diversity across cancer centers in the United States: opportunities and challenges.
Journal: Journal of the National Cancer Institute
Published: February 01, 2024
Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic cancer.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: January 24, 2024
Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.
Journal: BMJ case reports
Published: December 23, 2023
Last Updated: 09/26/2026